10.1016/S0024-3205(96)00606-6
Adi N., 2010, Melatonin MT1 and MT2 receptor expression in Parkinson's disease, Medical Science Monitor, 16
10.1371/journal.pone.0154427
10.1523/JNEUROSCI.18-09-03213.1998
10.1016/S0006-8993(02)02551-9
10.1016/S0143-4160(03)00141-6
10.1111/j.1600-079X.2005.00282.x
10.1016/j.lfs.2014.01.085
10.3727/000000003108746786
Bruni A. C., 1998, Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease: a Calabrian study, Functional Neurology, 13, 257
Brunner P., 2006, Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease, European Journal of Histochemistry, 50, 311
10.1111/j.1600-079X.2008.00637.x
10.1016/S1087-0792(98)90020-X
Cardinali D. P., 2012, Therapeutic application of melatonin in mild cognitive impairment, American Journal of Neurodegenerative Disease, 1, 280
10.1111/j.1600-079X.2007.00503.x
10.1111/j.1600-079X.2009.00700.x
10.1111/j.1600-079X.2006.00351.x
10.1016/j.freeradbiomed.2012.01.030
10.1016/j.neuchi.2015.03.002
10.1111/j.1600-079X.1998.tb00370.x
10.1111/j.1600-079X.2007.00553.x
10.1016/S0166-2236(99)01401-0
10.2174/1381612822666151204000733
10.1016/j.gene.2016.10.022
10.1523/JNEUROSCI.13-03-01065.1993
10.1097/WCO.0b013e3283050461
10.1111/j.1600-079X.2009.00664.x
10.1016/j.neuropharm.2008.05.031
10.1097/00019052-199612000-00017
10.1034/j.1600-079X.2001.310409.x
10.1016/j.jns.2014.01.002
10.1016/0891-5849(93)90172-Q
10.1080/10715760802255764
10.1227/01.NEU.0000351768.11363.48
10.1080/10408360290795547
Gupta Y. K., 2003, Neuroprotective role of melatonin in oxidative stress vulnerable brain, Indian Journal of Physiology and Pharmacology, 47, 373
10.1111/j.1600-079X.2008.00626.x
10.2174/157015910792246164
10.1111/j.1600-079X.2009.00701.x
10.1111/j.1742-7843.2006.pto_491.x
10.1046/j.1365-2125.2003.01933.x
Hattori A., 1995, Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates, Biochemistry and Molecular Biology International, 35, 627
10.2174/157015910792246137
Hirata F., 1974, In vitro and in vivo formation of two new metabolites of melatonin, The Journal of Biological Chemistry, 249, 1311, 10.1016/S0021-9258(19)42976-1
10.1212/WNL.0000000000004057
10.1097/00019052-200102000-00014
10.1111/j.1600-079X.2008.00616.x
Iriti M., 2009, Bioactivity of grape chemicals for human health, Natural Product Communications, 4, 611, 10.1177/1934578X0900400502
10.1016/j.chroma.2017.09.033
10.1034/j.1600-079X.2003.02937.x
Jeong S., 2017, Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease, Molecules and Cells, 40, 613, 10.14348/molcells.2017.0096
10.1097/00004647-199905000-00005
10.1111/j.1600-079X.2012.01005.x
10.1111/j.1600-079X.1999.tb00575.x
10.1111/j.1600-079X.2007.00420.x
10.1016/j.jns.2012.09.010
10.1111/j.1600-079X.2007.00456.x
10.1152/physrev.1999.79.4.1431
Liu R. Y., 1999, Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E‐epsilon4/4 genotype, The Journal of Clinical Endocrinology & Metabolism, 84, 323
10.1111/j.1600-079X.2007.00466.x
10.1097/00019442-200403000-00006
10.1111/j.1600-079X.2006.00391.x
Luboshitzky R., 2002, The effect of pyridoxine administration on melatonin secretion in normal men, Neuroendocrinology Letters, 23, 213
10.1186/s40035-017-0090-8
10.1007/s00702-010-0431-6
10.1016/S0024-3205(00)00896-1
10.1111/j.1600-079X.2008.00632.x
10.1016/S0891-5849(96)00629-6
10.1016/S0304-3940(02)00884-4
10.1034/j.1600-079X.2001.280309.x
10.1016/S0006-3223(97)00510-6
10.1007/s00441-002-0580-5
10.1016/S0079-6123(08)64566-5
10.1016/j.neuroscience.2015.10.044
10.1007/s11011-012-9310-1
10.1007/s00429-017-1439-6
10.1016/S0014-5793(00)02076-7
Obrenovitch T. P., 1996, Origins of glutamate release in ischaemia, Acta Neurochirurgica Supplement, 66, 50
10.1016/S0006-3223(98)00255-8
10.1111/j.1600-079X.2009.00692.x
10.1016/j.neurobiolaging.2011.10.015
10.1371/journal.pone.0001867
10.1016/j.neulet.2009.11.033
Padurariu M., 2013, The oxidative stress hypothesis in Alzheimer's disease, Psychiatria Danubina, 25, 401
10.1111/j.1471-4159.1980.tb11272.x
10.1016/j.neuro.2016.09.002
10.1146/annurev.neuro.21.1.479
10.1152/ajpregu.2000.278.5.R1339
10.1016/S1570-0232(02)00168-X
10.1016/j.freeradbiomed.2005.02.010
Rutten S., 2012, Bright light therapy in Parkinson's disease: an overview of the background and evidence, Parkinsons Disease, 2012
10.1111/j.1600-079X.2006.00412.x
10.1007/s00441-004-0938-y
Seiffert D., 2000, Presenilin‐1 and −2 are molecular targets for gamma‐secretase inhibitors, The Journal of Biological Chemistry, 275, 34086, 10.1074/jbc.M005430200
10.1016/S0962-8924(98)01363-4
10.1016/S0925-4439(00)00029-6
10.1111/j.1600-079X.2009.00720.x
10.2174/1570159X15666170313123454
10.1111/j.1600-079X.2005.00247.x
10.1111/j.1600-079X.2010.00819.x
10.1111/j.1749-6632.1999.tb07985.x
10.1016/0006-8993(90)90214-V
10.1016/0166-2236(95)93897-7
10.1046/j.1471-4159.1994.63041191.x
10.1034/j.1600-079X.2001.300408.x
10.1097/00004647-199801000-00002
10.1111/j.1471-4159.1990.tb08858.x
10.1111/j.1469-185X.2009.00118.x
10.1016/S0304-4165(99)00125-7
10.2174/157015910792246182
10.1111/j.1600-079X.2006.00407.x
10.1016/j.expneurol.2007.07.004
10.1111/j.1742-4658.2008.06302.x
10.1046/j.1600-079X.2003.00096.x
10.1016/0006-8993(96)00086-8
10.1007/s00228-005-0908-7
10.1016/j.molmed.2005.08.004
10.1001/jamaneurol.2013.6239
Weintraub D., 2008, Parkinson's disease–Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment, The American Journal of Managed Care, 14
10.1523/JNEUROSCI.18-06-02161.1998
10.1016/j.brainres.2008.03.083
10.1080/07420520701420717
10.1007/s10654-011-9581-6
10.1007/s10571-017-0461-9
10.1016/S0896-6273(00)80115-4
10.1016/S0002-9440(10)65396-5
10.1186/s13195-016-0206-x
10.1111/j.1600-079X.2008.00570.x
10.1034/j.1600-079X.2003.00065.x
ZigmondMJ B. R.Neuropsychopharmacology: The Fifth Generation of Progress.
Zimmermann R. C., 1993, Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans, The Journal of Clinical Endocrinology & Metabolism, 76, 1160
